CN1245215C - 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 - Google Patents
重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 Download PDFInfo
- Publication number
- CN1245215C CN1245215C CNB011043679A CN01104367A CN1245215C CN 1245215 C CN1245215 C CN 1245215C CN B011043679 A CNB011043679 A CN B011043679A CN 01104367 A CN01104367 A CN 01104367A CN 1245215 C CN1245215 C CN 1245215C
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- antigen
- interferon
- inhibiting rate
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
e抗原 | 细胞对照 16010 | 空白 0 | 稀释倍数 3 | IC50 602.74446016 | ||||||
浓度 | 第一孔 | 第二孔 | 第三孔 | 第一抑制率 | 第二抑制率 | 第三抑制率 | 平均抑制率 | 累加 | 1-累加 | 累加抑制率 |
900 | 9026 | 8976 | 10476 | 0.436227 | 0.43935 | 0.345659 | 0.407079 | 0.945909 | 0.592921 | 0.614693546 |
300 | 9616 | 12082 | 10098 | 0.3993754 | 0.245347 | 0.369269 | 0.337997 | 0.5388299 | 1.254924 | 0.300392321 |
100 | 9822 | 16002 | 12800 | 0.386508 | 0.0005 | 0.2005 | 0.195836 | 0.200833 | 2.059088 | 0.08867188 |
33.33333 | 15770 | 19306 | 16824 | 0.014991 | 0 | 0 | 0.004997 | 0.0049969 | 3.054091 | 0.001633453 |
11.11111 | 19172 | 22270 | 18934 | 0 | 0 | 0 | 0 | 0 | 4.054091 | 0 |
表面抗原 | 细胞对照 11714 | 空白 0 | 稀释倍数 3 | IC50 641.7736749 | ||||||
浓度 | 第一孔 | 第二孔 | 第三孔 | 第一抑制率 | 第二抑制率 | 第三抑制率 | 平均抑制率 | 累加 | 1-累加 | 累加抑制率 |
900 | 7706 | 7240 | 7114 | 0.342155 | 0.381936 | 0.392693 | 0.372261 | 0.922258 | 0.627739 | 0.595006426 |
300 | 8856 | 7778 | 9476 | 0.2439816 | 0.336008 | 0.191053 | 0.257014 | 0.5499972 | 1.370724 | 0.286349225 |
100 | 10818 | 10720 | 10330 | 0.07649 | 0.084856 | 0.118149 | 0.093165 | 0.292983 | 2.27756 | 0.113977019 |
33.33333 | 10744 | 11114 | 10570 | 0.082807 | 0.051221 | 0.097661 | 0.07723 | 0.1998179 | 3.20033 | 0.058767408 |
11.11111 | 10672 | 9352 | 10810 | 0.088953 | 0.201639 | 0.077173 | 0.122588 | 0.122588 | 4.077742 | 0.02918541 |
e抗原 | 细胞对照 16962 | 空白 0 | 稀释倍数 3 | IC50 365.9357846 | ||||||
浓度 | 第一孔 | 第二孔 | 第三孔 | 第一抑制率 | 第二抑制率 | 第三抑制率 | 平均抑制率 | 累加 | 1-累加 | 累加抑制率 |
900 | 7818 | 8516 | 9350 | 0.554378 | 0.514592 | 0.467054 | 0.512008 | 1.371181 | 0.487992 | 0.737521972 |
300 | 10344 | 10628 | 9160 | 0.4103967 | 0.394209 | 0.477884 | 0.427497 | 0.8591731 | 1.060496 | 0.447563245 |
100 | 12296 | 14228 | 13262 | 0.299134 | 0.18901 | 0.244072 | 0.244072 | 0.4316577 | 1.816423 | 0.19201839 |
33.33333 | 15364 | 17414 | 16188 | 0.124259 | 0.00741 | 0.77291 | 0.069653 | 0.1876045 | 2.74677 | 0.063933386 |
11.11111 | 17386 | 13632 | 15406 | 0.009006 | 0.222982 | 0.121865 | 0.117951 | 0.117951 | 3.628819 | 0.03148073 |
表面抗原 | 细胞对照 | 空白 0 | 稀释倍数 3 | IC50 611.0919568 | ||||||
浓度 | 第一孔 | 第二孔 | 第三孔 | 第一抑制率 | 第二抑制率 | 第三抑制率 | 平均抑制率 | 累加 | 1-累加 | 累加抑制率 |
900 | 5784 | 6198 | 5792 | 0.498265 | 0.462353 | 0.497571 | 0.486063 | 0.893477 | 0.513937 | 0.634835847 |
300 | 7150 | 8534 | 8318 | 0.379771 | 0.259715 | 0.278452 | 0.30598 | 0.4074138 | 1.207957 | 0.252210647 |
100 | 9830 | 11212 | 10210 | 0.147294 | 0.027412 | 0.11433 | 0.096345 | 0.101434 | 2.111612 | 0.04583464 |
33.33333 | 13942 | 12368 | 13478 | 0 | 0 | 0 | 0 | 0.0050891 | 3.111612 | 0.001632835 |
11.11111 | 12418 | 11634 | 11352 | 0 | 0 | 0.015267 | 0.005089 | 0.005089 | 4.106523 | 0.001237728 |
e抗原 | 细胞对照 17544 | 空白 0 | 稀释倍数 3 | IC50 382.0496935 | ||||||
浓度 | 第一孔 | 第二孔 | 第三孔 | 第一抑制率 | 第二抑制率 | 第三抑制率 | 平均抑制率 | 累加 | 1-累加 | 累加抑制率 |
900 | 9702 | 9614 | 8110 | 0.428016 | 0.433204 | 0.521872 | 0.461031 | 1.316983 | 0.538969 | 0.709599543 |
300 | 8914 | 10032 | 8870 | 0.4744723 | 0.40856 | 0.477066 | 0.453366 | 0.8559525 | 1.085603 | 0.440859127 |
100 | 16312 | 12688 | 13934 | 0.038321 | 0.251975 | 0.178517 | 0.156271 | 0.402586 | 1.929332 | 0.172641621 |
33.33333 | 15080 | 12814 | 13288 | 0.110954 | 0.244547 | 0.216602 | 0.190701 | 0.2463153 | 2.738631 | 0.082519158 |
11.11111 | 21928 | 15366 | 15728 | 0 | 0.094093 | 0.072751 | 0.0055615 | 0.055615 | 3.683017 | 0.014875633 |
表面抗原 | 细胞对照 11528 | 空白 0 | 稀释倍数 3 | IC50 694.7027149 | ||||||
浓度 | 第一孔 | 第二孔 | 第三孔 | 第一抑制率 | 第二抑制率 | 第三抑制率 | 平均抑制率 | 累加 | 1-累加 | 累加抑制率 |
900 | 5616 | 6228 | 5346 | 0.496864 | 0.442035 | 0.521054 | 0.486651 | 0.763125 | 0.513349 | 0.597838293 |
300 | 8542 | 8590 | 7096 | 0.234725 | 0.230425 | 0.364272 | 0.276474 | 0.2764738 | 1.236875 | 0.182690031 |
100 | 11420 | 11360 | 11394 | 0 | 0 | 0 | 0 | 0 | 2.236875 | 0 |
33.33333 | 12656 | 11582 | 13110 | 0 | 0 | 0 | 0 | 0 | 3.236872 | 0 |
11.11111 | 13142 | 12336 | 13342 | 0 | 0 | 0 | 0 | 0 | 4.236875 | 0 |
e抗原 | 细胞对照 17544 | 空白 0 | 稀释倍数 3 | IC50 FALSE | ||||||
浓度 | 第一孔 | 第二孔 | 第三孔 | 第一抑制率 | 第二抑制率 | 第三抑制率 | 平均抑制率 | 累加 | 1-累加 | 累加抑制率 |
300 | 14918 | 11724 | 9950 | 0 | 0.029711 | 0.176529 | 0.068747 | 0.068747 | 0.931253 | 0.068746724 |
100 | 14868 | 16890 | 15182 | 0 | 0 | 0 | 0 | 0 | 1.931253 | 0 |
33.33333 | 16760 | 21716 | 16400 | 0 | 0 | 0 | 0 | 0 | 2.931253 | 0 |
11.11111 | 20854 | 15042 | 16168 | 0 | 0 | 0 | 0 | 0 | 3.931253 | 0 |
3.703704 | 12083 | 12083 | 12083 | 0 | 0 | 0 | 0 | 0 | 4.931253 | 0 |
表面抗原 | 细胞对照 10886 | 空白 0 | 稀释倍数 3 | IC50 FALSE | ||||||
浓度 | 第一孔 | 第二孔 | 第三孔 | 第一抑制率 | 第二抑制率 | 第三抑制率 | 平均抑制率 | 累加 | 1-累加 | 累加抑制率 |
300 | 9226 | 8196 | 9658 | 0.152489 | 0.247106 | 0.521054 | 0.1708 | 0.189295 | 0.8292 | 0.185857736 |
100 | 10946 | 10340 | 10828 | 0 | 0.050156 | 0.364272 | 0.018495 | 0.0184947 | 1.810705 | 0.010110817 |
33.33333 | 12250 | 12980 | 13934 | 0 | 0 | 0 | 0 | 0 | 2.810705 | 0 |
11.11111 | 12634 | 12342 | 12000 | 0 | 0 | 0 | 0 | 0 | 3.810705 | 0 |
3.703704 | 10886 | 10886 | 10886 | 0 | 0 | 0 | 0 | 0 | 4.810705 | 0 |
Claims (6)
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011043679A CN1245215C (zh) | 2001-02-28 | 2001-02-28 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
DE60234085T DE60234085D1 (de) | 2001-02-28 | 2002-02-28 | Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor |
EP02702211A EP1371373B1 (en) | 2001-02-28 | 2002-02-28 | Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor |
CA002439503A CA2439503A1 (en) | 2001-02-28 | 2002-02-28 | Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor |
PCT/CN2002/000128 WO2002080958A1 (fr) | 2001-02-28 | 2002-02-28 | Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b |
JP2002578997A JP4617058B2 (ja) | 2001-02-28 | 2002-02-28 | コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用 |
AT02702211T ATE446104T1 (de) | 2001-02-28 | 2002-02-28 | Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor |
US10/650,365 US7364724B2 (en) | 2001-02-28 | 2003-08-28 | Recombinant super-compound interferon |
AU2003248419A AU2003248419B2 (en) | 2001-02-28 | 2003-09-26 | Recombinant super-compound interferon |
HK04104296.9A HK1061201A1 (en) | 2001-02-28 | 2004-06-15 | Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor |
US10/927,975 US20050079579A1 (en) | 2001-02-28 | 2004-08-26 | Uses of spatial configuration to modulate protein function |
US11/077,813 US20060035327A1 (en) | 2001-02-28 | 2005-03-10 | Recombinant super-compound interferon and uses thereof |
US12/105,455 US8114395B2 (en) | 2001-02-28 | 2008-04-18 | Treatment of viral diseases with recombinant interferon α |
US12/246,153 US8551469B2 (en) | 2001-02-28 | 2008-10-06 | Treatment of tumors and viral diseases with recombinant interferon alpha |
US12/889,521 US20110070195A1 (en) | 2001-02-28 | 2010-09-24 | Uses of spatial configuration to modulate protein function |
US13/019,044 US8425896B2 (en) | 2001-02-28 | 2011-02-01 | Treatment of tumors with recombinant interferon alpha |
US13/923,378 US20130281667A1 (en) | 2001-02-28 | 2013-06-21 | Uses of spatial configuration to modulate protein function |
US14/019,519 US9944686B2 (en) | 2001-02-28 | 2013-09-05 | Treatment of tumors with recombinant interferon alpha |
US15/910,165 US20180258151A1 (en) | 2001-02-28 | 2018-03-02 | Recombinant super-compound interferon and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011043679A CN1245215C (zh) | 2001-02-28 | 2001-02-28 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1311035A CN1311035A (zh) | 2001-09-05 |
CN1245215C true CN1245215C (zh) | 2006-03-15 |
Family
ID=4653854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011043679A Expired - Lifetime CN1245215C (zh) | 2001-02-28 | 2001-02-28 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
Country Status (10)
Country | Link |
---|---|
US (3) | US7364724B2 (zh) |
EP (1) | EP1371373B1 (zh) |
JP (1) | JP4617058B2 (zh) |
CN (1) | CN1245215C (zh) |
AT (1) | ATE446104T1 (zh) |
AU (1) | AU2003248419B2 (zh) |
CA (1) | CA2439503A1 (zh) |
DE (1) | DE60234085D1 (zh) |
HK (1) | HK1061201A1 (zh) |
WO (1) | WO2002080958A1 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060035327A1 (en) * | 2001-02-28 | 2006-02-16 | Guangwen Wei | Recombinant super-compound interferon and uses thereof |
US20050079579A1 (en) * | 2001-02-28 | 2005-04-14 | Guangwen Wei | Uses of spatial configuration to modulate protein function |
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
US7335496B2 (en) * | 2003-06-05 | 2008-02-26 | Ajinomoto Co., Inc. | Method for producing target substance |
US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
KR20150103335A (ko) * | 2003-08-28 | 2015-09-09 | 수퍼랩 파 이스트 리미티드 | 변경된 공간 구조를 갖는 인터페론의 용도 |
AU2011202683B2 (en) * | 2003-08-28 | 2012-08-09 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
EP2325202B1 (en) * | 2003-08-28 | 2014-10-22 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
CN1740197B (zh) * | 2004-08-26 | 2010-05-12 | 辉阳科技美国公司 | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 |
CN101137391B (zh) * | 2005-03-09 | 2012-07-18 | 魏光文 | 重组高效复合干扰素的用途 |
CN101525381B (zh) * | 2008-03-04 | 2012-04-18 | 北京百川飞虹生物科技有限公司 | 一种重组复合干扰素及其表达载体的构建和表达 |
CN102101886A (zh) | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
WO2013055811A1 (en) * | 2011-10-12 | 2013-04-18 | Hitachi Chemical Co., Ltd. | Ex vivo methods of predicting responsiveness of a subject to interferon therapy |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
DK2583677T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon |
TWI726291B (zh) | 2013-01-07 | 2021-05-01 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
WO2015070751A1 (en) | 2013-11-13 | 2015-05-21 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
CA2985524C (en) | 2015-05-12 | 2023-10-17 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4672108A (en) | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
DE3269727D1 (en) | 1981-12-07 | 1986-04-10 | Hoffmann La Roche | Crystalline human leukocyte interferon |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4462940A (en) | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
US4681930A (en) | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
EP0626448A3 (de) | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
DE4329756A1 (de) | 1993-09-03 | 1995-03-09 | Boehringer Ingelheim Int | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
EP0861321B1 (en) | 1995-10-13 | 2006-05-31 | President And Fellows Of Harvard College | Phosphopantetheinyl transferases and uses thereof |
US5972331A (en) | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
US6532437B1 (en) | 1996-10-23 | 2003-03-11 | Cornell Research Foundation, Inc. | Crystalline frap complex |
CN1186120A (zh) | 1996-12-24 | 1998-07-01 | 深圳科兴生物制品有限公司 | 在大肠杆菌中表达作为分泌的重组人干扰素α1b蛋白 |
US6114145A (en) * | 1997-12-05 | 2000-09-05 | Human Genome Sciences, Inc. | Synferon, a synthetic interferon |
US6087478A (en) | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
BR9907964A (pt) | 1998-02-06 | 2000-10-17 | Ilexus Pty Limited | Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos |
CN1062565C (zh) | 1998-06-29 | 2001-02-28 | 深圳九先生物工程有限公司 | 重组人α型复合干扰素及其制备方法和用途 |
KR100399156B1 (ko) | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
CN1175901C (zh) | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | 一种稳定的干扰素水溶液 |
US20020043262A1 (en) | 2000-08-22 | 2002-04-18 | Alan Langford | Spray device |
US7544354B2 (en) | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
EP1355939A2 (en) | 2000-11-03 | 2003-10-29 | Pestka Biomedical Laboratories, Inc. | Interferons, uses and compositions related thereto |
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
US6546074B1 (en) | 2001-03-27 | 2003-04-08 | Astex Technology Limited | Protein crystal structure and method for identifying protein modulators |
CN1375502A (zh) | 2001-10-25 | 2002-10-23 | 南京药科大学 | 聚乙二醇修饰重组人干扰素 |
US6807478B2 (en) * | 2001-12-27 | 2004-10-19 | Koninklijke Philips Electronics N.V. | In-building navigation system |
CN1176946C (zh) | 2002-05-16 | 2004-11-24 | 中国人民解放军第二军医大学 | 一种新型α干扰素 |
CN1202861C (zh) | 2003-07-18 | 2005-05-25 | 中国科学院微生物研究所 | 复合干扰素在治疗sars疾病中的用途 |
EP2325202B1 (en) | 2003-08-28 | 2014-10-22 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
CN101137391B (zh) | 2005-03-09 | 2012-07-18 | 魏光文 | 重组高效复合干扰素的用途 |
-
2001
- 2001-02-28 CN CNB011043679A patent/CN1245215C/zh not_active Expired - Lifetime
-
2002
- 2002-02-28 DE DE60234085T patent/DE60234085D1/de not_active Expired - Lifetime
- 2002-02-28 WO PCT/CN2002/000128 patent/WO2002080958A1/zh active Application Filing
- 2002-02-28 EP EP02702211A patent/EP1371373B1/en not_active Expired - Lifetime
- 2002-02-28 AT AT02702211T patent/ATE446104T1/de not_active IP Right Cessation
- 2002-02-28 JP JP2002578997A patent/JP4617058B2/ja not_active Expired - Lifetime
- 2002-02-28 CA CA002439503A patent/CA2439503A1/en not_active Abandoned
-
2003
- 2003-08-28 US US10/650,365 patent/US7364724B2/en not_active Expired - Lifetime
- 2003-09-26 AU AU2003248419A patent/AU2003248419B2/en not_active Expired
-
2004
- 2004-06-15 HK HK04104296.9A patent/HK1061201A1/xx not_active IP Right Cessation
-
2008
- 2008-04-18 US US12/105,455 patent/US8114395B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,044 patent/US8425896B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1311035A (zh) | 2001-09-05 |
US20080305080A1 (en) | 2008-12-11 |
JP4617058B2 (ja) | 2011-01-19 |
WO2002080958A1 (fr) | 2002-10-17 |
HK1061201A1 (en) | 2004-09-10 |
CA2439503A1 (en) | 2002-10-17 |
EP1371373A4 (en) | 2005-05-04 |
US8425896B2 (en) | 2013-04-23 |
AU2003248419B2 (en) | 2007-01-04 |
JP2005508848A (ja) | 2005-04-07 |
AU2003248419A1 (en) | 2003-11-06 |
US20040202641A1 (en) | 2004-10-14 |
EP1371373B1 (en) | 2009-10-21 |
US20110189128A1 (en) | 2011-08-04 |
ATE446104T1 (de) | 2009-11-15 |
US7364724B2 (en) | 2008-04-29 |
DE60234085D1 (de) | 2009-12-03 |
US8114395B2 (en) | 2012-02-14 |
EP1371373A1 (en) | 2003-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1245215C (zh) | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 | |
CN1699408A (zh) | 高效抑制血管生成多肽及其制备方法和应用 | |
CN101812438B (zh) | 一种精氨酸脱亚氨酶突变体及其制备与应用 | |
CN1876676A (zh) | 抗肿瘤寡肽及其制备方法和应用 | |
CN1526725A (zh) | 抗肿瘤多肽及其应用 | |
US8287852B2 (en) | Treatment of viral diseases with recombinant interferon α | |
CN1363558A (zh) | 蛙皮抗菌肽衍生物 | |
CN1740197B (zh) | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 | |
CN108578386A (zh) | 通过靶向肿瘤相关巨噬细胞递送抑制肿瘤生长的miRNA的药物及应用 | |
CN101001644B (zh) | 空间构象改变的干扰素及其应用 | |
CN1062565C (zh) | 重组人α型复合干扰素及其制备方法和用途 | |
CN1369550A (zh) | 一种金黄色葡萄球菌的培养物及其制备方法 | |
CN1745847A (zh) | 用精氨酸酶治疗肝炎的药物组合物和方法 | |
CN85107120A (zh) | 重组体dna及其用途 | |
SU897099A3 (ru) | Способ получени вещества кS-2-а,обладающего противоопухолевым и антимикробным действием | |
CN1883709A (zh) | 导向双功能抗肿瘤多肽及其应用 | |
CN102294020A (zh) | 空间构象改变的干扰素及其应用 | |
RU2380405C2 (ru) | Способ получения рекомбинантного альфа 16-интерферона человека и фармацевтическая композиция для лечения вирусных заболеваний на основе рекомбинантного альфа 16-интерферона человека | |
RU2326944C2 (ru) | Способ получения и препарат аналога рекомбинантного интерферона гамма человека | |
CN1748790A (zh) | 一种天门冬酰胺酶注射液、其制备方法及应用 | |
CN101302252B (zh) | 一种胸腺素alphal(Tαl)类似物及生产工艺和医用途 | |
CN101041066B (zh) | 重组鲨肝刺激物质类似物用于治疗慢性肝脏疾病的用途 | |
CN1197482C (zh) | 苷肽组合物、其制备方法和应用 | |
RU2089911C1 (ru) | Способ иммунокоррекции при висцеральном кандидозе | |
CN1274362C (zh) | 一种预防和治疗艾滋病药物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN HUIYANG LIFE SCIENCE AND TECHNOLOGY CORP. Free format text: FORMER OWNER: SICHUAN PROV. BIOLOGICAL ENGINEERING RESEARCH CENTRE Effective date: 20101102 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610017 NO.85, HONGXING MIDDLE ROAD, CHENGDU CITY, SICHUAN PROVINCE TO: 610063 ROOM 402, 4/F, BUILDING A, YINHAI STAR, NO.163, SANSE ROAD, JINJIANG DISTRICT, CHENGDU CITY, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101102 Address after: 610063, Sichuan, Jinjiang District, Chengdu three color road 163, Yinhai core block A, building 4, room 402 Patentee after: Sichuan Huiyang Life Engineering Co., Ltd. Address before: 610017 No. 85 Hongxing Road, Sichuan, Chengdu Patentee before: Sichuan Prov. Biological Engineering Research Centre |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151222 Address after: The British Virgin Islands of Tortola Patentee after: SUPERLAB FAR EAST LTD. Address before: 610063, Sichuan, Jinjiang District, Chengdu three color road 163, Yinhai core block A, building 4, room 402 Patentee before: Sichuan Huiyang Life Engineering Co., Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20060315 |
|
CX01 | Expiry of patent term |